Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Brief description of study
This research study is investigating a drug as a possible treatment for metastatic renal cell
carcinoma. The intervention involved in this study is TAK-228.
Clinical Study Identifier: NCT03097328
Detailed Study Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational intervention to learn whether the intervention works
in treating a specific disease. "Investigational" means that the intervention is being
The FDA (the U.S. Food and Drug Administration) has not approved TAK-228 as a treatment for
any disease but it is being investigated as a treatment for advanced solid tumors, blood
disorders, and inflammatory diseases. TAK-228 works to inhibit or interfere with cellular
functions involved in cell growth and survival. TAK-228 specifically targets a type of
protein that can make chemicals that trigger cell growth, including cancer cell growth. This
protein may also cause cells to produce proteins that trigger the development of new blood
vessels. Cancers need new blood vessels in order to grow. In some types of cancer, this type
of protein (mTOR) is switched on, and it makes the cancer cells grow and produce new blood
vessels. mTOR blockers (inhibitors) are a newer type of cancer growth blocker that can stop
the growth of some types of cancer.
Researchers hope to learn how participants with previously treated mRCC will respond to
treatment with TAK-228. Other goals of this study include assessing the types of side effects
associated TAK-228 and whether there is a relationship between certain genetic mutations
(changes to your DNA) and participant responses to the drug.